| The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma L Moreno, C Perez, A Zabaleta, I Manrique, D Alignani, D Ajona, L Blanco, ... Clinical Cancer Research 25 (10), 3176-3187, 2019 | 181 | 2019 |
| PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017 T Jelinek, J Mihalyova, M Kascak, J Duras, R Hajek Immunology 152 (3), 357-371, 2017 | 142 | 2017 |
| Update on PD-1/PD-L1 inhibitors in multiple myeloma T Jelinek, B Paiva, R Hajek Frontiers in immunology 9, 2431, 2018 | 113 | 2018 |
| Extramedullary disease in multiple myeloma–controversies and future directions S Sevcikova, J Minarik, M Stork, T Jelinek, L Pour, R Hajek Blood reviews 36, 32-39, 2019 | 93 | 2019 |
| Venetoclax: A new wave in hematooncology J Mihalyova, T Jelinek, K Growkova, M Hrdinka, M Simicek, R Hajek Experimental hematology 61, 10-25, 2018 | 90 | 2018 |
| Current applications of multiparameter flow cytometry in plasma cell disorders T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, ... Blood cancer journal 7 (10), e617, 2017 | 68 | 2017 |
| Cytogenetics in multiple myeloma patients progressing into extramedullary disease L Besse, L Sedlarikova, H Greslikova, R Kupska, M Almasi, M Penka, ... European Journal of Haematology 97 (1), 93-100, 2016 | 57 | 2016 |
| Plasma cell leukemia: From biology to treatment T Jelinek, F Kryukov, L Rihova, R Hajek European journal of haematology 95 (1), 16-26, 2015 | 56 | 2015 |
| Monoclonal antibodies—A new era in the treatment of multiple myeloma T Jelinek, R Hajek Blood reviews 30 (2), 101-110, 2016 | 52 | 2016 |
| Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination JJ Garcés, M Simicek, M Vicari, L Brozova, L Burgos, R Bezdekova, ... Leukemia 34 (2), 589-603, 2020 | 51 | 2020 |
| PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future T Jelinek, R Hajek OncoImmunology 5 (12), e1254856, 2016 | 49 | 2016 |
| Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma E Terpos, K Ramasamy, N Maouche, J Minarik, I Ntanasis-Stathopoulos, ... Annals of Hematology 99, 1049-1061, 2020 | 45 | 2020 |
| Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t (11; 14) T Jelinek, J Mihalyova, M Kascak, J Duras, T Popkova, K Benkova, ... American journal of hematology 94 (1), E35-E37, 2019 | 37 | 2019 |
| Intercellular Mitochondrial Transfer in the Tumor Microenvironment H Sahinbegovic, T Jelinek, M Hrdinka, JR Bago, M Turi, T Sevcikova, ... Cancers 12 (7), 1787, 2020 | 32 | 2020 |
| Monoclonal antibodies in the treatment of AL amyloidosis: co‐targetting the plasma cell clone and amyloid deposits T Popkova, R Hajek, T Jelinek British Journal of Haematology 189 (2), 228-238, 2020 | 31 | 2020 |
| Limited efficacy of daratumumab in multiple myeloma with extramedullary disease T Jelinek, T Sevcikova, D Zihala, T Popkova, V Kapustova, ... Leukemia 36 (1), 288-291, 2022 | 30 | 2022 |
| Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients D Vrabel, L Sedlarikova, L Besse, L Rihova, R Bezdekova, M Almasi, ... European journal of haematology 104 (3), 190-197, 2020 | 27 | 2020 |
| Immunomodulatory drugs in AL amyloidosis T Jelinek, Z Kufova, R Hajek Critical reviews in oncology/hematology 99, 249-260, 2016 | 27 | 2016 |
| Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine … J Minarik, T Pika, J Radocha, A Jungova, J Straub, T Jelinek, L Pour, ... BMC cancer 21, 1-13, 2021 | 26 | 2021 |
| Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the … H Ludwig, W Pönisch, S Knop, A Egle, A Hinke, M Schreder, D Lechner, ... Leukemia & lymphoma 61 (2), 377-386, 2020 | 25 | 2020 |
